ULTRAGENYX PHARMACEUTICAL INC. Share-based Payment Arrangement, Noncash Expense
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Share-based Payment Arrangement, Noncash Expense of $38.36 million for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-03.
Discontinued › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2018-08-03
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, noncash expense for the quarter ending 2018-06-30 was $19.56M, a 16.49% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, noncash expense for the quarter ending 2018-03-31 was $18.80M, a 29.64% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, noncash expense for the quarter ending 2017-12-31 was $19.54M, a 44.34% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, noncash expense for the quarter ending 2017-09-30 was $17.18M, a 25.46% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, noncash expense for fiscal 2017 was $68.01M, a 40.79% increase from fiscal 2016.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, noncash expense for fiscal 2016 was $48.31M, a 94.14% increase from fiscal 2015.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, noncash expense for fiscal 2015 was $24.88M, a 361.33% increase from fiscal 2014.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, noncash expense for fiscal 2014 was $5.39M, a 721.00% increase from fiscal 2013.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 47 month |
|---|---|---|---|---|---|
| 2018-06-30 | $19.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $38.36M 10-Q · filed 2018-08-03 | $57.90M derived: sum of 3 quarters · filed 2018-08-03 | $75.08M derived: sum of 4 quarters · filed 2018-08-03 | |
| 2018-03-31 | $18.80M 10-Q · filed 2018-05-08 | $38.34M derived: sum of 2 quarters · filed 2018-05-08 | $55.52M derived: sum of 3 quarters · filed 2018-05-08 | $72.31M derived: sum of 4 quarters · filed 2018-08-03 | |
| 2017-12-31 | $19.54M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $36.72M derived: sum of 2 quarters · filed 2018-02-21 | $53.52M derived: sum of 3 quarters · filed 2018-08-03 | $68.01M 10-K · filed 2018-02-21 | |
| 2017-09-30 | $17.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $33.97M derived: sum of 2 quarters · filed 2018-08-03 | $48.47M 10-Q · filed 2017-11-03 | $62.01M derived: sum of 4 quarters · filed 2018-08-03 | |
| 2017-06-30 | $16.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $31.29M 10-Q · filed 2018-08-03 | $44.83M derived: sum of 3 quarters · filed 2018-08-03 | $58.52M derived: sum of 4 quarters · filed 2018-08-03 | |
| 2017-03-31 | $14.50M 10-Q · filed 2018-05-08 | $28.04M derived: sum of 2 quarters · filed 2018-05-08 | $41.73M derived: sum of 3 quarters · filed 2018-05-08 | $52.59M derived: sum of 4 quarters · filed 2018-05-08 | |
| 2016-12-31 | $13.54M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $27.23M derived: sum of 2 quarters · filed 2018-02-21 | $38.09M derived: sum of 3 quarters · filed 2018-02-21 | $48.31M 10-K · filed 2018-02-21 | |
| 2016-09-30 | $13.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $24.55M derived: sum of 2 quarters · filed 2017-11-03 | $34.77M 10-Q · filed 2017-11-03 | $44.26M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2016-06-30 | $10.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $21.08M 10-Q · filed 2017-07-28 | $30.57M derived: sum of 3 quarters · filed 2018-02-21 | $38.46M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2016-03-31 | $10.22M 10-Q · filed 2017-05-05 | $19.71M derived: sum of 2 quarters · filed 2018-02-21 | $27.60M derived: sum of 3 quarters · filed 2018-02-21 | $32.69M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2015-12-31 | $9.49M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $17.39M derived: sum of 2 quarters · filed 2018-02-21 | $22.48M derived: sum of 3 quarters · filed 2018-02-21 | $24.88M 10-K · filed 2018-02-21 | |
| 2015-09-30 | $7.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | $12.99M derived: sum of 2 quarters · filed 2016-11-08 | $15.39M 10-Q · filed 2016-11-08 | $17.40M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-06-30 | $5.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $7.50M 10-Q · filed 2016-08-09 | $9.50M derived: sum of 3 quarters · filed 2017-02-17 | $11.15M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-03-31 | $2.41M 10-Q · filed 2016-05-10 | $4.41M derived: sum of 2 quarters · filed 2017-02-17 | $6.06M derived: sum of 3 quarters · filed 2017-02-17 | $7.01M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2014-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $3.65M derived: sum of 2 quarters · filed 2017-02-17 | $4.60M derived: sum of 3 quarters · filed 2017-02-17 | $5.39M 10-K · filed 2017-02-17 | |
| 2014-09-30 | $1.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $2.60M derived: sum of 2 quarters · filed 2015-11-10 | $3.39M 10-Q · filed 2015-11-10 | $3.60M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2014-06-30 | $946.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $1.74M 10-Q · filed 2015-08-14 | $1.95M derived: sum of 3 quarters · filed 2016-02-26 | $2.02M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2014-03-31 | $795.00K 10-Q · filed 2015-05-12 | $1.00M derived: sum of 2 quarters · filed 2016-02-26 | $1.08M derived: sum of 3 quarters · filed 2016-02-26 | $1.26M derived: sum of 4 quarters · filed 2016-02-26 | $2.60M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $210.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $281.00K derived: sum of 2 quarters · filed 2016-02-26 | $466.00K derived: sum of 3 quarters · filed 2016-02-26 | $657.00K 10-K · filed 2016-02-26 | |
| 2013-09-30 | $71.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $256.00K derived: sum of 2 quarters · filed 2014-11-10 | $447.00K 10-Q · filed 2014-11-10 | ||
| 2013-06-30 | $185.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $376.00K 10-Q · filed 2014-08-11 | |||
| 2013-03-31 | $191.00K 10-Q · filed 2014-05-12 | ||||
| 2012-12-31 | $891.00K 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |